Cara Therapeutics | CARA - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Assertio Holdings USD 16.73M 1.66M 2024-09
Cara Therapeutics USD 2.19M 2.45M 2025-09
Cassava Sciences USD 6.66M 1.24M 2025-12
Chugai Pharma JPY 36.93B 9.04B 2025-12
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.21M 120K 2025-12
CSL USD 1.23B 498M 2025-12
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
J&J USD 6.03B 719M 2026-03
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pacira USD 91.87M 70K 2025-12
Pfizer USD 4.08B 894M 2025-12
RedHill Biopharma USD 4.48M 1.52M 2024-03
Supernus Pharmaceuticals USD 122.39M 57.29M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12